Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients
Open Access
- 16 April 2012
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 25 (6) , 680-686
Abstract
We compared steady-state pharmacokinetics of mycophenolate mofetil (MMF) – Myfenax® (Teva) and CellCept® (Roche) – in stable kidney transplant recipients (KTRs). This was an international, multi-centre, randomized, open-label, two-treatment, two-sequence crossover study with a 3-month follow-up. We included KTRs at least 12 months post-transplantation with stable renal graft function for at least 3 months. The maintenance treatment consisted of MMF in combination with tacrolimus with or without steroids. At the end of the two treatment periods, 6-h or 12-h PK studies of mycophenolic acid (MPA) were performed. A total of 43 patients (mean age: 50.7 ± 13.5 years; 19 females, 24 males) were randomized. Estimates of test to reference ratios (90% CIs) were 0.959 (0.899; 1.023) h*μg/ml for AUC(0–tau) and 0.873 (0.787; 0.968) μg/ml for Cmax. Estimates for AUC(0–6h) were 0.923 (0.865; 0.984) h*μg/ml and 0.985 (0.877; 1.106) μg/ml for Cmin. Thus, AUC(0–tau), AUC(0–6h), and Cmin of MPA were within the predefined margins. Cmax was somewhat outside of these margins in this set of patients. The numbers and types of adverse events were not different between the two treatments. The steady-state pharmacokinetics of MPA as well as adverse events are comparable for Myfenax® and CellCept® in tacrolimus-treated stable KTRs. (EudraCT-No.: 2009-010562-31; ClinicalTrials.Gov number: NCT00991510)Keywords
This publication has 24 references indexed in Scilit:
- European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive DrugsTransplant International, 2011
- Randomized Trial of Immunosuppressive Regimens in Renal TransplantationJournal of the American Society of Nephrology, 2011
- Immunosuppression, Generic Drugs and the FDAAmerican Journal of Transplantation, 2011
- The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft FunctionAmerican Journal of Transplantation, 2011
- Impact of maintenance immunosuppressive regimens - balance between graft protective suppression of immune functions and a near physiological immune responseTransplant International, 2011
- Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physiciansTransplant International, 2010
- Mycophenolate mofetil 500-mg tablet under fasting conditions: Single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjectsClinical Therapeutics, 2010
- Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trialKidney International, 2010
- Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysisKidney International, 2010
- Mycophenolate mofetil and its mechanisms of actionImmunopharmacology, 2000